NCT05976334View on ClinicalTrials.gov

An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

November 14, 2023

Primary Completion Date

June 21, 2024

Study Completion Date

July 16, 2024

Conditions
Solid Tumors
Interventions
DRUG

[14C] Subasumstat

\[14C\] Subasumstat IV infusion.

DRUG

Subasumstat

Subasumstat IV infusion.

Trial Locations (2)

1062

Central Hospital of Northern Pest - Military Hospital, Budapest

1077

Pharmaceutical Research Associates Magyarorszag, Budapest

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT05976334 - An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter